Our Portfolio
Export table
FILTERS
Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Dossier Availability
Select some options
PRODUCT NAME
THERAPEUTIC AREA
PHARMACEUTICAL
FORM
STRENGTH
REFERENCE
PRODUCT
DOSSIER
AVAILABILITY
Alimentary tract & metabolism
Film-coated tablets
10 mg/5 mg
25 mg/5 mg
Glyxambi/ Boehringer Ingelheim
2024 Q4
Alimentary tract & metabolism
Film-coated tablets
5/850 mg
5/1000 mg
Xigduo / Astra Zeneca
2022 Q4
Alimentary tract & metabolism
Film-coated tablets
5mg/500mg
5mg/850mg
5mg/1000 mg
12.5mg/500mg
12.5mg/850mg
12.5mg/1000mg
Synjardy / Boehringer Ingelheim
2025 Q1
Alimentary tract & metabolism
Film-coated tablets
2.5/500 mg
2.5/850 mg
2.5/1000 mg
Jentadueto / Boehringer Ingelheim
2022 Q4
Cardiovascular System
Film-coated tablets
24mg / 26mg
49mg / 51mg
97mg / 103mg
Entresto / Novartis
2022 Q4 (CA) / 2023 Q4 (EU)
Respiratory system
Inhalation powder
85/43 mcg
Ultibro Breezhaler / Novartis
2024 Q1
Antineoplastic & Immunomodulating Agents
Film-coated tablets
10 mg
20 mg
30 mg
Otezla / Celgene
2023 Q3 (EU)
Antineoplastic & Immunomodulating Agents
Prolonged-release tablet
11 mg
Xeljanz / Pfizer
Early stage
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
^ This product is not offered for sale or made available in Germany due to patent (SPC) protection.
DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
Our Portfolio
Empagliflozin* / Linagliptin*^
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Glyxambi/ Boehringer Ingelheim
STRENGTH
10 mg/5 mg
| 25 mg/5 mg
DOSSIER AVAILABILITY
2024 Q4
Dapagliflozin* / Metformin (1)^
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Xigduo / Astra Zeneca
STRENGTH
5/850 mg
| 5/1000 mg
DOSSIER AVAILABILITY
2022 Q4
Empagliflozin* / Metformin^
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Synjardy / Boehringer Ingelheim
STRENGTH
5mg/500mg
| 5mg/850mg
| 5mg/1000 mg
| 12.5mg/500mg
| 12.5mg/850mg
| 12.5mg/1000mg
DOSSIER AVAILABILITY
2025 Q1
Linagliptin* / Metformin (2)^
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Jentadueto / Boehringer Ingelheim
STRENGTH
2.5/500 mg
| 2.5/850 mg
| 2.5/1000 mg
DOSSIER AVAILABILITY
2022 Q4
Nebivolol
THERAPEUTIC AREA
Cardiovascular System
PHARMACEUTICAL FORM
Tablets
REFERENCE PRODUCT
Nebilet / Menarini
STRENGTH
5 mg
| 10 mg
DOSSIER AVAILABILITY
2022 Q4
Sacubitril / Valsartan (3)
THERAPEUTIC AREA
Cardiovascular System
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Entresto / Novartis
STRENGTH
24mg / 26mg
| 49mg / 51mg
| 97mg / 103mg
DOSSIER AVAILABILITY
2022 Q4 (CA) / 2023 Q4 (EU)
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
^ This product is not offered for sale or made available in Germany due to patent (SPC) protection.
